Modum Acquired by Roambee to Dominate the Pharma Cold Chain Market

Modum, which is a European Pharma last mile-focused cold chain monitoring player based in Zurich, Switzerland, has been acquired by Roambee, a Silicon Valley-based global supply chain visibility provider. Roambee will extend its cold chain visibility offering from end to end, including primary, secondary, and last-mile delivery use-cases. As a result of this acquisition, it was solidifying its leadership position in real-time cold chain monitoring systems.

Roambee’s real-time supply chain visibility platform combines its firsthand sensor inputs with non-sensor data to ensure that shipments and assets arrive on schedule, complete, and in excellent shape. Roambee’s supply chain signals and intelligence are used by 300+ customers worldwide, including one of the largest US-based COVID-19 vaccine manufacturers.

Modum, a company that has received $13.5 million since its launch in 2016, provides proven pharma-grade monitoring solutions. Even in the most complex logistics scenarios needing high volume and minimal touch, such as last-mile delivery transactions, Modum “plug and play” solutions succeed. Its low unit cost of monitoring and adherence to all pharma quality compliance criteria provide last-mile delivery visibility to organizations like Swiss Post.Modum has created revolutionary systems that use two-factor authentication to identify wireless loggers with shipments and feed data into blockchain networks for authenticity, bringing transparency and unrivaled integrity to location and condition data.

Simon Dössegger, Modum CEO, said, “Joining forces with Roambee was natural for Modum due to our shared mission to ensure the timely availability of effective, original products in the medical supply chain. Modum will enhance Roambee’s cold chain footprint with a proven last mile visibility technology to extend the Roambee product proposition to a unique global end-to-end visibility solution. When combined with Roambee’s strong multimodal shipment monitoring capabilities, we can offer granular visibility all the way from manufacturing to a patient’s home at scale.”